Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF)

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

August 24, 2018

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Atrial Fibrillation
Interventions
DRUG

Metformin

Metformin ER 500 mg daily, titrated at 1 month intervals to 500 mg twice daily, then 750 mg twice daily, as tolerated, for 2 years.

BEHAVIORAL

Lifestyle/Risk Factor Modification

Diet/nutrition counseling and exercise prescription with follow-up visits, sleep apnea screening and treatment if detected, optimization of guideline-directed medical therapies for hypertension, coronary artery disease (CAD), hyperlipidemia and heart failure (HF).

Trial Locations (1)

44195

Cleveland Clinic, Cleveland

All Listed Sponsors
collaborator

American Heart Association

OTHER

collaborator

The Cleveland Clinic

OTHER

lead

Mina Chung, MD

OTHER